Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

Supplements and Featured PublicationsInhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

This publication was funded and developed by United Therapeutics.

This AJMC® Clinical Brief summarizes results of the pivotal study by Aaron Waxman MD, PhD, et al published in The New England Journal of Medicine on the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease.

© 2023 MJH Life Sciences
AJMC®
All rights reserved.